Mar, 22 2019 11:37 JST

Source: Eisai

Eisai's Initiation of Phase III Clinical Trial of BAN2401 in Early Alzheimer's Disease


TOKYO, Mar, 22 2019 - (JCN Newswire) - Eisai Co., Ltd. announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer's disease has been initiated. BAN2401 is being jointly developed by Eisai and Biogen Inc.

Clarity AD is a global placebo-controlled, double-blind, parallel-group, randomized study in 1,566 patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease dementia (collectively known as early AD) with confirmed amyloid pathology in the brain. After discussion with regulatory agencies based on the results of a Phase II clinical study (Study 201), a single Phase III clinical study is being initiated to support a filing for BAN2401.

The treatment group will be administered a dosage of 10 mg/kg bi-weekly of BAN2401, with patients allocated in a 1:1 ratio to receive either placebo or the treatment group. The primary endpoint is the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment. Respective changes from baseline to 18 months of treatment in the AD composite score (ADCOMS), AD Assessment Scale-Cognitive Subscale (ADAS-cog), and brain amyloid levels as measured by amyloid positron emission tomography (PET) have been set as key secondary endpoints.

Eisai aims to create innovative medicines for Alzheimer's disease as soon as possible in order to further contribute to addressing the unmet medical needs of, as well as potentially increasing the benefits provided to, patients and their families.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting
May 29 2019 09:05 JST
 
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets
May 17 2019 15:34 JST
 
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting
May 16 2019 07:37 JST
 
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan
May 10 2019 12:34 JST
 
Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401
May 10 2019 11:55 JST
 
Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions
May 09 2019 11:33 JST
 
Eisai Commences Venture Investment Business Aimed at Accelerating Innovation in Drug Creation and Establishment of Ecosystem Platform
May 09 2019 11:06 JST
 
Eisai and UK Dementia Research Institute Jointly Launch New Post-Doctoral Programme to Accelerate Dementia Research
May 08 2019 08:37 JST
 
Eisai Buys Out Purdue Rights to End Collaboration
May 01 2019 08:09 JST
 
Eisai to Present Latest Data on Lemborexant and Perampanel at Annual American Academy of Neurology Meeting
April 24 2019 16:53 JST
 
More Press release >>

Latest Press Release


More Latest Release >>